Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

64.26 +0.83 (+1.31%)
Streaming Delayed Price Updated: 3:30 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cidara Therapeutics, Inc. - Common Stock

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
From Phathom Pharmaceuticals
Via GlobeNewswire
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
CDTX INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
WHY: NEW YORK, NY - (NewMediaWire) - May 16, 2024 - Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cidara... 
Via TheNewswire.com
Topics Regulatory Compliance
CDTX INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
From The Rosen Law Firm PA
Via GlobeNewswire
CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
CDTX LOSS ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
WHY: NEW YORK, NY - (NewMediaWire) - May 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara... 
Via TheNewswire.com
Topics Regulatory Compliance
CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
From The Rosen Law Firm, P.A.
Via Business Wire
5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science
From 5AM Venture Management, LLC
Via GlobeNewswire
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
From Melinta Therapeutics, LLC
Via Business Wire
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
From Melinta Therapeutics, LLC
Via Business Wire
Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022
From Cidara Therapeutics, Inc.
Via GlobeNewswire
Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
From Cidara Therapeutics, Inc.
Via GlobeNewswire
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
From Cidara Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.